Onkologische Schwerpunktpraxis Bielefeld
Industry / private company
Location:
Bielefeld,
Germany (DE)
ISNI: 000000405581094
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019)
Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al.
Journal article
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017)
Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, et al.
Journal article